CAR-T cell precise therapy for hematologic malignancies:four key breakthroughs,existing problems and solutions
10.3872/j.issn.1007-385x.2025.02.001
- VernacularTitle:CAR-T细胞精准治疗血液恶性肿瘤发展进程中的四大突破及其存在的问题和解决对策
- Author:
Meifang LI
1
;
Lijuan ZHOU
1
;
Yuhua LI
1
Author Information
1. 南方医科大学珠江医院 血液内科,广东 广州 510282;精准免疫细胞治疗技术广东省工程研究中心,广东 广州 510282
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor gene-modified T lymphocyte(CAR-T cell);
precise therapy;
hematologic malignancies;
humanized;
dual target;
multi-target;
universal;
combination strategy
- From:
Chinese Journal of Cancer Biotherapy
2025;32(2):127-139
- CountryChina
- Language:Chinese
-
Abstract:
Hematologic malignancies are a severe threat to human health.CAR-T cell therapy,as a highly effective treatment for hematologic malignancies,has become one of the fastest developing cancer immunotherapies in recent years.To obtain highly effective and low-toxicity CAR-T cells,through continuous development and exploration,CAR-T cell therapy has achieved a series of significant breakthroughs in treating hematologic malignancies,including humanized CAR-T cell technology,dual-target and multitarget CAR-T cell technology,universal CAR-T cell technology,and CAR-T cell combination strategy technology.Humanized CAR-T cell technology reduces immunogenicity through humanized modification.Dual-target and multi-target CAR-T cell technology recognizes two or more tumor antigens,minimizes antigen escape and enhance efficacy.Universal CAR-T cell technology solves problems such as high cost and accessibility issues.The CAR-T cell combination strategy technology effectively deals with CAR-T recurrence and enhances efficacy and safety by combining different treatment methods.Although CAR-T cell therapy has achieved significant breakthroughs in the treatment of hematologic malignancies,it still faces challenges such as drug resistance,antigen escape,cytotoxicity,and posttreatment recurrence.This review presents the significant breakthroughs,existing problems,and solutions for CAR-T cell precise therapy for hematological malignancies.
